Actos Bladder Cancer Lawsuit

Actos Bladder Cancer News

Actos-Bladder-Cancer-Lawsuit-300x187On June 15th, 2011, the FDA announced that use of Actos for more than one year may be associated with an increased risk of bladder cancer. If you feel you may qualify or just have a few questions, we can help.

Actos Lawsuit Help Line 1-800-499-6652

Actos or Pioglitazone (HCI) is a drug manufactured by Takeda Pharmaceuticals and was marketed for use with treating adults with Type 2 Diabetes.

This information is drawn upon from the FDA’s five-year interim analysis and their ongoing ten-year epidemiological study.

The five-year study showed that despite there being no overall increased risk of bladder cancer in patients that use Actos, there is still an increased risk of bladder cancer in patients that use Actos over long periods of time and also in those exposed to the highest doses of Actos.

The FDA is aware of a recent epidemiological study of Actos in France which shows an increased risk of Actos bladder cancer in patients who were prescribed the drug.

Based on this study, France has suspended the use of Actos and Germany has recommended not to prescribe Actos to new patients.

If you have taken Actos you may be entitled to an Actos Bladder Cancer Lawsuit.

Actos Bladder Cancer Research

Studies are noted in medical journals like the British Medical Journal and the New England Journal of Medicine that explain the risks of taking Actos and the chances of developing Actos bladder cancerwhen taking Actos for more than one year.

The New England Journal of Medicine’s website, Journal Watch, reported that researchers had identified 116,000 patients with type 2 diabetes that were new users of oral antidiabetic drugs and that after a follow-up of less than 5 years, 470 patients were diagnoses with Actos bladder cancer.

Patients who used Actos were associated with having 83% higher risk of developing bladder cancer, a dramatic increase than those compared with patients who had never taken Actos. The rate of bladder cancer increased significantly with:

  • Length of Actos use
  • The highest rates in patients who were exposed for less than 2 years
  • In patients whose collective, long term dosage exceeded 28,000mg.

Additionally, websites such as, trusted online medical source WebMD and even on the American Diabetes Association website all discuss the risks, side effects and the increased risk of Actos bladder cancer with patients. With all the information available to the public, Actos Bladder Cancer Lawsuit are increasing and

According to a recent study reported on WebMD, researchers analyzed over 115,000 patients between 1988 and 2009 who have taken Actos for more than two years were determined to have double the risk of developing Actos bladder cancer when compared to patients who have never taken Actos. According to WebMD, a spokesperson for Takeda Pharmaceuticals in Deerfield, Ill., did supply the following statement:

“Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes more than 12 years of clinical and patient experience with the product.”

“As a company, Takeda is committed to ongoing clinical research to understand and investigate potential safety concerns, and is currently supporting several ongoing studies, including a 10-year epidemiological study, investigating the potential relationship between Actos and bladder cancer.”

Seeking Help with your Actos Bladder Cancer Lawsuit

Maximize your possible claim in an Actos Bladder Cancer Lawsuit today by contacting our lawyers to find out if you may qualify.

Leave a Reply

Your email address will not be published. Required fields are marked *